NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the recommended dose of NC-6004 according to the dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy, safety and tolerability.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NanoCarrier Co., Ltd.
• Collaborator: Orient Europharma Co., Ltd.
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• Patients with chemo-naive, advanced pancreatic cancer

• Nonresectable, histologically or cytologically confirmed, locally advanced or metastatic pancreatic cancer

Exclusion Criteria:

• Pulmonary fibrosis or interstitial pneumonia

• Marked pleural effusion or ascites above Grade 2

• Severe drug hypersensitivity

• Metastasis to the central nervous system and brain